Dr. Quon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
403 W. Adams Blvd.
Los Angeles, CA 90007Phone+1 213-742-1000Fax+1 213-742-1000- Is this information wrong?
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2003
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1996 - 1999
- David Geffen School of Medicine at UCLAClass of 1996
Certifications & Licensure
- CA State Medical License 1998 - 2025
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
Clinical Trials
- Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A Start of enrollment: 2013 Mar 01
- Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B Start of enrollment: 2013 Feb 11
- Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- 5 citationsA Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.Glenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, Fabricio Racca, Doris Quon, Serge Leyvraz, Dagmar Hess, Bhumsuk Keam, Jordi Rodon, Myung-Ju Ahn, Hye Ryun Kim, ...> ;Cancer Research Communications. 2023 Sep 14
- 2 citationsA Phase I/II Investigation of Safety and Efficacy of Nivolumab and-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway.Erlinda M Gordon, Nicole L Angel, Nadezhda Omelchenko, Victoria S Chua-Alcala, Ania Moradkhani, Doris Quon, Steven Wong> ;Anticancer Research. 2023 May 1
- 24 citationsTwo-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.Johnny Mahlangu, Radoslaw Kaczmarek, Annette von Drygalski, Susan Shapiro, Sheng-Chieh Chou, Margareth C Ozelo, Gili Kenet, Flora Peyvandi, Michael Wang, Bella Madan, ...> ;The New England Journal of Medicine. 2023 Feb 23
- Join now to see all
Journal Articles
- BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia ADoris V Quon, Margaret V Ragni, The New England Journal of Medicine
- Development and Reliability of the Joint Tissue Activity and Damage Examination for Quantitation of Structural Abnormalities by Musculoskeletal Ultrasound in Hemophili...Eric Y Chang, Annette von Drygalski, Doris V Quon, Tudor H Hughes, Journal of Ultrasound in Medicine
Press Mentions
- BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia AJanuary 2nd, 2020
- Clinical Challenge: From Pediatric to Adult Hemophilia CareDecember 17th, 2019
- California's Most Expensive Patient in Recent Years Has HemophiliaMarch 6th, 2018
Hospital Affiliations
- Cedars-Sinai Medical CenterLos Angeles, California
- Keck Hospital of USCLos Angeles, California
- Ronald Reagan UCLA Medical CenterLos Angeles, California
- Providence Saint John's Health CenterSanta Monica, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: